Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05640999


Additional trial details provided through ANZCTR are available at the end of this record.


Registration number
NCT05640999
Ethics application status
Date submitted
29/11/2022
Date registered
7/12/2022
Date last updated
21/10/2024

Titles & IDs
Public title
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Scientific title
A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER)
Secondary ID [1] 0 0
NRG-GY032
Secondary ID [2] 0 0
EN10
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Endometrial Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Womb (Uterine or endometrial cancer)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Vaginal brachytherapy
Treatment: Other - Adjuvant radiotherapy (EBRT +/- brachytherapy)
Other interventions - Observation

Experimental: Sub-study A: RAINBO BLUE Cohort A1 - Observation

Experimental: Sub-Study A: RAINBO BLUE Cohort A2 Exploratory - Observation or Adjuvant Radiotherapy

Experimental: Sub-Study B: TAPER - Observation or Vaginal Brachytherapy


Treatment: Other: Vaginal brachytherapy
Vaginal brachytherapy should be delivered using a vaginal cylinder, or alternatively ovoids

Treatment: Other: Adjuvant radiotherapy (EBRT +/- brachytherapy)
Treatment is to be delivered using 4-18 MV photons. MV, kV or CBCT imaging capabilities are required. Planning systems with capability for DICOM data transfer must be used.

Other interventions: Observation
Observation
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Estimate the rate of pelvic recurrence at 3 years in patients who are treated with de-escalated adjuvant treatment directed by tumour molecular status
Timepoint [1] 0 0
3 years
Secondary outcome [1] 0 0
Estimate the rate of isolated vaginal recurrence at 3 years
Timepoint [1] 0 0
3 years
Secondary outcome [2] 0 0
Estimate the rate of para-aortic recurrence at 3 years
Timepoint [2] 0 0
3 years
Secondary outcome [3] 0 0
Estimate the rate of distant metastasis at 3 years
Timepoint [3] 0 0
3 years
Secondary outcome [4] 0 0
Estimate recurrence-free survival
Timepoint [4] 0 0
9 years
Secondary outcome [5] 0 0
Estimate endometrial cancer-specific survival
Timepoint [5] 0 0
9 years
Secondary outcome [6] 0 0
Estimate overall survival
Timepoint [6] 0 0
9 years
Secondary outcome [7] 0 0
Describe the impact of molecular classification on fear of recurrence by Fear of Recurrence Inventory
Timepoint [7] 0 0
9 years

Eligibility
Key inclusion criteria
* Patients must have had surgery consisting of hysterectomy and bilateral salpingo-oophorectomy. Lymph node dissection can be performed as per institutional standards. There must be no macroscopic residual disease after surgery.
* Patients must have histologically confirmed Stage I to III endometrial carcinoma which can be endometrioid, serous, clear cell, un/dedifferentiated, carcinosarcoma or mixed.
* Patients' Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2.
* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
* Patients' age must be = 18 years.
* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements.
* Patient is able (i.e. sufficiently fluent) and willing to complete the patient-reported outcomes (PRO) questionnaires in either English, French or a validated language
* Patients must be accessible for treatment and follow-up. Patients enrolled on this trial must be treated and followed at the participating centre
* Protocol treatment is to begin within 10 weeks of hysterectomy/bilateral salpingo-oophorectomy
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior Neoadjuvant chemotherapy for current endometrial cancer diagnosis.
* Prior pelvic radiation.
* Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for = 5 years.
* Clinical evidence of distant metastasis as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT scan) (

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/12/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/06/2029
Actual
Sample size
Target
325
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
South Western Sydney Local Health District - Liverpool
Recruitment hospital [2] 0 0
Westmead Hospital - Westmead
Recruitment hospital [3] 0 0
Mater Research Institute South Brisbane - South Brisbane
Recruitment hospital [4] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [5] 0 0
Frankston Hospital - Frankston
Recruitment hospital [6] 0 0
The Royal Women's Hospital - Victoria Park
Recruitment hospital [7] 0 0
Canberra Hospital - Garran
Recruitment hospital [8] 0 0
Royal Brisbane and Womens Hospital - Herston
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
3168 - Clayton
Recruitment postcode(s) [5] 0 0
3199 - Frankston
Recruitment postcode(s) [6] 0 0
3053 - Victoria Park
Recruitment postcode(s) [7] 0 0
ACT 2605 - Garran
Recruitment postcode(s) [8] 0 0
4029 - Herston
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Massachusetts
Country [2] 0 0
United States of America
State/province [2] 0 0
Utah
Country [3] 0 0
Canada
State/province [3] 0 0
Alberta
Country [4] 0 0
Canada
State/province [4] 0 0
British Columbia
Country [5] 0 0
Canada
State/province [5] 0 0
Ontario
Country [6] 0 0
Canada
State/province [6] 0 0
Quebec
Country [7] 0 0
Italy
State/province [7] 0 0
Milan
Country [8] 0 0
Netherlands
State/province [8] 0 0
Gelderland
Country [9] 0 0
Netherlands
State/province [9] 0 0
Limburg
Country [10] 0 0
Netherlands
State/province [10] 0 0
Noord Brabant
Country [11] 0 0
Netherlands
State/province [11] 0 0
Leiden
Country [12] 0 0
Netherlands
State/province [12] 0 0
Rotterdam
Country [13] 0 0
New Zealand
State/province [13] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Other
Name
Canadian Cancer Trials Group
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Canadian Cancer Clinical Trials Network
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies

* EN10.A/RAINBO BLUE: POLE-mutated EC
* EN10.B/TAPER: p53 wildtype / NSMP EC
Trial website
https://clinicaltrials.gov/study/NCT05640999
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Kathy Han
Address 0 0
University Health Network, Princess Margaret Hospital, Toronto ON Canada
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Wendy Parulekar
Address 0 0
Country 0 0
Phone 0 0
613-533-6430
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05640999

Additional trial details provided through ANZCTR
Accrual to date
Recruiting in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 172
Westmead Hospital
Recruitment postcode(s) [1] 173
2145
Funding & Sponsors
Primary sponsor
Other Collaborative groups
Primary sponsor name
Australia New Zealand Gynaecological Oncology Group (ANZGOG)
Primary sponsor address
Level 6, Lifehouse 119-143 Missenden Road Camperdown NSW 2050
Primary sponsor country
Australia
Ethics approval
Ethics application status
Approved
Ethics committee name [1] 72
WSLHD HREC
Address [1] 72
Country [1] 72
Australia
Date submitted for ethics approval [1] 72
20/07/2023
Approval date [1] 72
13/10/2023
Ethics approval number [1] 72
 
Public notes

Contacts
Principal investigator
Title 425 0
Prof
Name 425 0
Alison Brand
Address 425 0
Country 425 0
Australia
Phone 425 0
Fax 425 0
Email 425 0
[email protected]
Contact person for public queries
Title 426 0
Mrs
Name 426 0
Lisa Bailey
Address 426 0
Country 426 0
Australia
Phone 426 0
Fax 426 0
Email 426 0
[email protected]
Contact person for scientific queries
Title 427 0
Name 427 0
Address 427 0
Country 427 0
Phone 427 0
Fax 427 0
Email 427 0